Exact Sciences Drops $75M on Blood Test Like It’s Hot
In a move that screams 'We want it first or we want it all,' Exact Sciences is shelling out a whopping $75 million to snag exclusive rights to a blood-based 'liquid biopsy' from rival Freenome. Because nothing says friendly competition like locking down your neighbor's science project. To quote the deal, Exact Sciences is paying for 'exclusive rights'—so if you wanted a sneak peek at this fancy blood test, tough luck. Apparently, in the world of medical high-stakes poker, $75 million is just the ante.
Share the Story
(1 of 3)Exact Sciences just bought a blood test like it was the last Pumpkin Spice Latte. Exclusive rights for $75M proves medicine now prefers monopolies over miracles. Thanks, capitalism!
Nothing says friendship like a $75 million handshake to keep your rival’s blood test under lock and key. Science today: where billion-dollar block parties happen in lab coats.
Exact Sciences is basically the kid who snatches the shared toy and screams 'Mine!' but with $75 million. Blood tests have never been so possessive.
Source: Statnews | Published: 8/6/2025 | Author: Jonathan Wosen
More Articles in Health
OpenAI CEO’s $27M Mansion Molotoved Amid AI Lab Soap Opera
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Digital Nomad Trapped in Lisbon FOMO, Ends Up BFF Ghosted
Couple Rejects Costco Bulk, Returns to European Grocery Steps and Sanity
Woman Befriends Octogenarian, Learns Aging Is Just 'Old Lady' Bluntness
Woman’s Routine Eye Surgery Turns Into Unplanned MRI Brain Tumor Scare Roadshow
Health Secretary Trades Vaccines for Vegetable Advocacy and Congressional Grousing
Doctors Prescribe Fishing Rods—Because Pills Can’t Cast a Line
